GSK GSK plc
USHealthcareAs of 2026-07-10 16:00
Why GSK matters now
GSK plc (GSK) is a US stock in Healthcare. The latest InvestLog snapshot shows $52.78 with +0.59% on the session and $105.71B in market capitalization; recent performance reads 1-month -0.74% and YTD +3.32%.
The latest financial table shown here is Q1 2026, with revenue of $7.63B, net income of $1.74B, and EPS of $0.86. Investors can compare that operating picture with valuation signals such as P/E 20.18 and FCF yield 6.5%.
The latest indexable market news headline is "GSK's targeted cancer therapy shows positive results in late-stage study" from Reuters.
Additional event context on this page matters because analyst consensus is Hold with a median target of $53.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
20.18
PEG
0.17
P/B
4.34
P/S
2.35
EV/EBITDA
8.02
DCF Value
$307.84
FCF Yield
6.5%
Div Yield
3.5%
Margins & Returns
Gross Margin
72.7%
Operating Margin
22.3%
Net Margin
17.8%
ROE
35.8%
ROA
9.3%
ROIC
13.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.63B | $1.74B | $0.86 |
| Q4 2025 | $8.62B | $636.0M | $0.82 |
| FY 2025 | $32.67B | $5.72B | $5.56 |
| Q3 2025 | $8.55B | $2.01B | $1.00 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$52.45
Target (Median)
$53.00
Target Range
$35.25 - $85.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
GB
Exchange
—
Beta
0.29
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.